Indian Healthcare sector is at crossroads. Challenges are many, ranging from rising dual disease burden –both Communicable Disease (CD) and Non-Communicable Disease (NCD) burden, quality, access, affordability, health infrastructure, financing, rational pricing of essential devices, trust deficit between stakeholders, lack of clear policies and regulatory framework. The growing ageing population and rise in cost of their healthcare needs are exerting considerable demands on the health systems. Today, the Indian government spends only about 1.4% of its GDP on healthcare, which is among the lowest globally for any country. There is a need to focus more on raising the investment in healthcare in the country (PwC Report).
The BioSpectrum India edition was launched in March 2003 and is India's first comprehensive biotech business monthly magazine. It provides comprehensive coverage of the exciting happenings in life sciences, which include BioPharma, BioAgriculture, BioInformatics, BioIndustrial, BioSuppliers and BioServices and show cases the emerging Indian entrepreneurships in biotech industry. In a short time BioSpectrum has emerged as the most preferred platform to engage the life sciences industry in India and Asia Pacific. It is also widely accepted by research and academia community. Top key policy makers in the Central and state government use the magazine as a platform to reach out the Indian Biotech Industry. BioSpectrum has columns by Indian's top policy makers, biotechnology professionals, scientists and NGOs. Readers of BioSpectrum are from among the key Policy Makers, Key Executives and the Influencer's in Biotechnology, Pharmaceutical Companies, Research Heads of Clinical Research, Clinical Trials and Contract Mfg Organizations, Educational Institutes, Consultants, Fund Managers etc